XNAS
CELZ
Market cap10mUSD
Jul 09, Last price
3.94USD
1D
46.47%
1Q
118.89%
IPO
34,160.87%
Name
Creative Medical Technology Holdings Inc
Chart & Performance
Profile
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
IPO date
May 01, 2009
Employees
4
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 11 22.22% | 9 -89.84% | 89 0.96% | |||||||
Cost of revenue | 2,405 | 1,974 | 6,297 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (2,394) | (1,965) | (6,209) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (100) | |||||||||
Tax Rate | ||||||||||
NOPAT | (2,394) | (1,965) | (6,108) | |||||||
Net income | (5,493) 3.91% | (5,287) -47.36% | (10,044) -167.26% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,455 | (271) | 15,472 | |||||||
BB yield | -42.53% | 4.18% | -3,713.64% | |||||||
Debt | ||||||||||
Debt current | 14 | |||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 3,268 | |||||||||
Net debt | (5,940) | (9,987) | (18,385) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (5,301) | (8,028) | (7,797) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 6,320 | 3,445 | (10,079) | |||||||
Cash from financing activities | 1,455 | (271) | 15,472 | |||||||
FCF | (2,394) | (1,965) | (6,108) | |||||||
Balance | ||||||||||
Cash | 5,940 | 9,987 | 18,399 | |||||||
Long term investments | ||||||||||
Excess cash | 5,940 | 9,987 | 18,395 | |||||||
Stockholders' equity | (64,590) | (59,097) | (53,798) | |||||||
Invested Capital | 70,932 | 69,441 | 69,677 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 1,480 | 1,408 | 1,093 | |||||||
Price | 2.31 -49.89% | 4.61 1,109.66% | 0.38 -82.76% | |||||||
Market cap | 3,420 -47.30% | 6,489 1,457.58% | 417 -41.97% | |||||||
EV | (2,521) | (3,498) | (17,968) | |||||||
EBITDA | (2,284) | (1,871) | (6,117) | |||||||
EV/EBITDA | 1.10 | 1.87 | 2.94 | |||||||
Interest | 100 | |||||||||
Interest/NOPBT |